Reprint

Diabetic Foot Complications: Current Challenges and Future Prospects—Part II

Edited by
May 2024
222 pages
  • ISBN978-3-7258-0913-4 (Hardback)
  • ISBN978-3-7258-0914-1 (PDF)

This book is a reprint of the Special Issue Diabetic Foot Complications: Current Challenges and Future Prospects—Part II that was published in

Medicine & Pharmacology
Public Health & Healthcare
Summary

Diabetic foot is a growing complication due to the global increase in diabetes mellitus prevalence; this disease affects 9.1 to 26.1 million people annually, and between 19% and 34% of people develop diabetes at least once in their life. Diabetic foot is sometimes associated with lower limb amputations and higher rates of mortality than certain types of cancer, such as breast or prostate cancer. In recent years, research has focused on managing the main complications that lead to limb loss, such as diabetic foot infections or peripheral vascular disease. The majority of studies have investigated the outcomes in the acute phase when the patient has a complicated diabetic foot ulcer. However, long-term studies, randomized control trials, and studies on prevention, both primary and secondary, are still scarce in the literature. In addition, the benefits of multidisciplinary teams on patient outcomes, health care system organization, the competences of different specialities and health care professionals, and the impact of different organizational and structural approaches are not yet well studied. This Special Issue discusses the current state of the art, addresses ongoing knowledge gaps, and focuses on ongoing controversies related to diabetic foot complications.

Format
  • Hardback
License
© 2024 by the authors; CC BY-NC-ND license
Keywords
peripheral blood mononuclear cells; PBMNCs; cell therapy; critical limb ischemia; no-option critical limb ischemia; NO-CLI; diabetic foot; major amputation; amputation-free survival; AFS; wound healing; diabetic foot; diabetic foot ulcer; diabetic neuropathy; sleep; obstructive sleep apnea; laser speckle contrast imaging; diabetes mellitus; diabetes complications; foot ulcer; microcirculation; peripheral artery disease; wound healing; diabetic foot ulcer; type 2 diabetes; quality of life; psychometric validation; reliability; validity; Antibiofilmogram; antibiotics; biofilm; diabetic foot infections; Staphylococcus aureus; wound healing; wound healing; diabetic foot; immune system; monocytes; lymphocytes; macrophage polarization; tissue regeneration; clinical practice; diabetes; foot risk; nutritional status; ultrasound assisted wound debridement; diabetic foot ulcers; diabetic foot; treatment; diabetic foot complications; mortality risk; hospitalizations; first ever incident diabetic foot hospital admission; amputations; diabetic foot ulcers; diabetics; diabetic’s foot infection; cardiovascular/stroke risk stratification; deep learning; AI bias; wound healing; amputations; ischaemia; diabetic foot; ankle/brachial index; toe/brachial index; diabetic foot; living skin equivalents; classification; wound healing; keratinocytes; diabetic foot; neuroischaemic diabetic foot ulcer; microcirculation; sucrose octasulfate dressing; transcutaneous oxygen pressure; diabetic patients; surgical site infection; elective orthopedic surgery; diabetic foot; diabetic foot ulcer; digital deformity; flexor tenotomy; diabetic foot ulcers; diabetic foot infection; Charcot foot reconstruction; diabetic foot osteomyelitis; biocomposite; calcium sulphate